Statin use among patients without prior CVD identified as being at risk
| Total at risk (n (%)) | Number of at risk patients on statin, n (%) | Number of untreated at risk patients, n (% total population) | |
|---|---|---|---|
| FRS | 5/266 (1.6) | 1/5 (20) | 4/266 (1.5) |
| NCEP | 58/294 (21.7) | 3/64 (5.2) | 55/294 (18.7) |
| SCORE (TC:HDL) | 43/166 (25.9) | 18/43 (41.8) | 25/166 (15.1) |
| Reynolds Risk Score | 45/291 (15.5) | 5/45 (11.1) | 40/291 (13.7) |
CVD, cardiovascular disease; FRS, Framingham Risk Score; HDL, high-density lipoproteins; LDL, low-density lipoproteins; NCEP, National Cholesterol Education Program; SCORE, systematic coronary risk evaluation according to total cholesterol: high-density lipoprotein risk tables; TC, total cholesterol.